These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 10917549)

  • 1. Characterization and modulation of drug resistance of human paediatric rhabdomyosarcoma cell lines.
    Cocker HA; Pinkerton CR; Kelland LR
    Br J Cancer; 2000 Aug; 83(3):338-45. PubMed ID: 10917549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro prevention of the emergence of multidrug resistance in a pediatric rhabdomyosarcoma cell line.
    Cocker HA; Tiffin N; Pritchard-Jones K; Pinkerton CR; Kelland LR
    Clin Cancer Res; 2001 Oct; 7(10):3193-8. PubMed ID: 11595714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High levels of the MDM2 oncogene in paediatric rhabdomyosarcoma cell lines may confer multidrug resistance.
    Cocker HA; Hobbs SM; Tiffin N; Pritchard-Jones K; Pinkerton CR; Kelland LR
    Br J Cancer; 2001 Nov; 85(11):1746-52. PubMed ID: 11742497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MDM2 and p21WAF1/CIP1, wild-type p53-induced proteins, are regularly expressed by Sternberg-Reed cells in Hodgkin's disease.
    Sánchez-Beato M; Piris MA; Martínez-Montero JC; García JF; Villuendas R; García FJ; Orradre JL; Martínez P
    J Pathol; 1996 Sep; 180(1):58-64. PubMed ID: 8943816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines.
    Keshelava N; Zuo JJ; Chen P; Waidyaratne SN; Luna MC; Gomer CJ; Triche TJ; Reynolds CP
    Cancer Res; 2001 Aug; 61(16):6185-93. PubMed ID: 11507071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
    Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
    Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional and gene expression analysis of the p53 signaling pathway in clear cell sarcoma of the kidney and congenital mesoblastic nephroma.
    Brownlee NA; Hazen-Martin DJ; Garvin AJ; Re GG
    Pediatr Dev Pathol; 2002; 5(3):257-68. PubMed ID: 12007018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein.
    Keleti J; Quezado MM; Abaza MM; Raffeld M; Tsokos M
    Am J Pathol; 1996 Jul; 149(1):143-51. PubMed ID: 8686737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CIAPIN1 confers multidrug resistance through up-regulation of MDR-1 and Bcl-L in LoVo/Adr cells and is independent of p53.
    Zhang YF; Li XH; Shi YQ; Wu YY; Li N; He Q; Ji Q; Wang RQ; Yang SM; Fang DC
    Oncol Rep; 2011 Apr; 25(4):1091-8. PubMed ID: 21240465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p21WAF1/CIP1 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MDM2-, p21-immunophenotype associated with missense p53 mutations.
    Villuendas R; Pezzella F; Gatter K; Algara P; Sánchez-Beato M; Martínez P; Martínez JC; Muñoz K; García P; Sánchez L; Kocialkowsky S; Campo E; Orradre JL; Piris MA
    J Pathol; 1997 Jan; 181(1):51-61. PubMed ID: 9072003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 may mediate the mdr-1 expression via the WT1 gene in human vincristine-resistant leukemia/lymphoma cell lines.
    Hirose M; Kuroda Y
    Cancer Lett; 1998 Jul; 129(2):165-71. PubMed ID: 9719458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein.
    Landers JE; Cassel SL; George DL
    Cancer Res; 1997 Aug; 57(16):3562-8. PubMed ID: 9270029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity.
    Piovesan B; Pennell N; Berinstein NL
    Oncogene; 1998 Nov; 17(18):2339-50. PubMed ID: 9811465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of human gastric carcinoma cell lines with induced multidrug resistance.
    Kang MS; Kim HS; Han JA; Park SC; Kim WB; Park JG
    Anticancer Res; 1997; 17(5A):3531-6. PubMed ID: 9413198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bax is an important determinant of chemosensitivity in pediatric tumor cell lines independent of Bcl-2 expression and p53 status.
    McPake CR; Tillman DM; Poquette CA; George EO; Houghton JA; Harris LC
    Oncol Res; 1998; 10(5):235-44. PubMed ID: 9802058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel gene P28GANK confers multidrug resistance by modulating the expression of MDR-1, Bcl-2 and Bax in osteosarcoma cells.
    Wang G; Rong J; Zhou Z; Duo J
    Mol Biol (Mosk); 2010; 44(6):1010-7. PubMed ID: 21287809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells.
    Morgan SE; Kim R; Wang PC; Bhat UG; Kusumoto H; Lu T; Beck WT
    Oncogene; 2000 Oct; 19(43):5010-9. PubMed ID: 11042688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P21/waf1 protein expression in nasopharyngeal carcinoma. Comparative study with PCNA, p53 and MDM-2 protein expression.
    Kouvidou C; Stefanaki K; Dai Y; Tzardi M; Koutsoubi K; Darivianaki K; Karidi E; Rontogianni D; Zois E; Kakolyris S; Georgoulias V; Delides G; Kanavaros P
    Anticancer Res; 1997; 17(4A):2615-9. PubMed ID: 9252690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The process behind the expression of mdr-1/P-gp and mrp/MRP in human leukemia/lymphoma.
    Hirose M
    Anticancer Res; 2009 Apr; 29(4):1073-7. PubMed ID: 19414348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
    Sjöström J; Blomqvist C; Heikkilä P; Boguslawski KV; Räisänen-Sokolowski A; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Bergh J; Wist E; Valvere V; Saksela E
    Clin Cancer Res; 2000 Aug; 6(8):3103-10. PubMed ID: 10955790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.